EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Taro Pharmaceutical Industries Ltd. - TARO

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Taro Pharmaceutical Industries Ltd. securities (NYSE:TARO) from July 3, 2014 through September 9, 2016, both dates inclusive (the "Class Period").

To join the Taro Pharmaceutical class action, go to http://www.rosenlegal.com/cases-971.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or kchan@rosenlegal.com for information on the class action.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.

According to the lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) since 2014 Taro Pharmaceutical has colluded with other pharmaceutical companies to keep the price of generic products artificially high; (2) the foregoing conduct violated federal antitrust laws; (3) in turn, Taro Pharmaceutical's revenues during the Class Period were the result of illegal conduct; and (4) as a result, Taro Pharmaceutical's public statements were materially false and misleading at all relevant times. On September 9, 2016, Taro Pharmaceutical revealed that its subsidiary and two senior officers received grand jury subpoenas from the United States Department of Justice, Antitrust Division, seeking documents regarding the sale of generic pharmaceutical products. On this news, shares of Taro Pharmaceutical fell $4.94 per share or almost 4% to close at $119.42 per share on September 23, 2016. On October 17, 2016, NECA-IBEW Welfare Trust Fund filed an antitrust class action lawsuit against Taro Pharmaceutical and several other pharmaceutical companies alleging that they engaged in the price-fixing of Clobetasol since 2014 in violation of the U.S. antitrust laws.

If you liked this article you might like

Perrigo, Taro Show Perils of Failure to Branch in Branded Drugs

Generics Drop Across Board as DOJ Inquiry Expands

Perrigo Stock Sliding on DOJ Search

4 Blue-Chip Health-Care Picks on Sale (and the Portfolio Is Up 163% Since 2006)

Impax Searches for a New CEO